ASSESSING THE SAFETY AND EFFICACY OF A 2MG DOSE OF TH9507, A GROWTH HORMONE RELE

评估 2 毫克剂量 TH9507（一种生长激素相关药物）的安全性和有效性

• 批准号: 7731337
• 负责人: STEVEN K. GRINSPOON
• 金额: $ 1.56万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731337
• 关键词: Body Composition; Central obesity; Computer Retrieval of Information on Scientific Projects Database; Dose; Exhibits; Funding; Goals; Grant; HIV; HIV-Associated Lipodystrophy Syndrome; High Density Lipoprotein Cholesterol; Hyperinsulinism; Institution; Insulin-Like Growth Factor I; Link; Lipids; Lipodystrophy; Metabolic; Obesity; Patients; Pharmaceutical Preparations; Population; Quality of life; Research; Research Personnel; Resources; Safety; Somatotropin; Somatotropin-Releasing Hormone; Source; TH9507; Triglycerides; United States National Institutes of Health; Visceral; abdominal fat; antiretroviral therapy; impaired glucose tolerance

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary goal of the stduy is to determine the safety and efficacy of the medication TH9507, a growth hormone releasing factor, in reducing excess visceral adiposity associated with HIV lipodystrophy. Secondary objectives include improvements in total cholesterol/HDL ratio, triglyceride levels, changes in IGF-1 and improvement in quality of life and characterization of the safety profile of TH9507 treatment in HIV subjects with excess abdominal fat accumulation. HIV infected patients treated with antiretroviral therapy commonly exhibit body composition changes and metabolic abnormalities, termed the HIV lipodystrophy syndrome. Increased visceral adiposity has been associated with abnormal lipid profiles, hyperinsulinemia and impaired glucose tolerance in this population. Reduced growth hormone levels have been implicated as a potential link between abdominal obesity and metabolic disturbances.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目标是确定药物TH9507的安全性和有效性，TH9507是一种生长激素释放因子，在减少与艾滋病毒脂肪营养不良相关的内脏过度肥胖方面。次要目标包括改善总胆固醇/高密度脂蛋白比率、甘油三酯水平、IGF-1的变化和生活质量的改善，以及TH9507治疗腹部脂肪堆积过多的艾滋病毒患者的安全性特征。 接受抗逆转录病毒治疗的HIV感染者通常会出现身体成分变化和代谢异常，称为HIV脂营养不良综合征。在这些人群中，内脏肥胖症的增加与血脂异常、高胰岛素血症和糖耐量受损有关。生长激素水平降低被认为是腹型肥胖和代谢紊乱之间的潜在联系。